Laurus Labs shares in focus after board approves Rs 83.3 crore investment in KRKA Pharma
Laurus Labs will be in focus on Friday after the company approved an investment of Rs 83.3 crore in KRKA Pharma Pvt Ltd, a joint venture.
In addition, KRKA d.d., Novo Mesto, Slovenia (the co-venturer), will invest Rs 86.7 crore in KRKA Pharma, thereby maintaining the current shareholding ratio of 51:49 between KRKA d.d., Novo Mesto, and Laurus Labs.
“The purpose of this investment is to acquire land and cover the initial costs of establishing a manufacturing facility for the production of finished products targeting new markets, including the Indian market. This investment is in line with the company’s strategic growth plans and long-term business goals,” the company said in its press release.
KRKA, a joint venture was established under the Companies Act, 2013. The authorized share capital of KRKA is Rs 270 crore consisting of 27 crore equity shares valued at Rs 10 each. The paid-up share capital amounts to Rs 45 crore divided into 4.5 crore equity shares, also priced at Rs 10 each. The target entity was incorporated on April 12, 2024.
Laurus Labs share price
Stock Trading
Maximise Returns by Investing in the Right Companies
By — The Economic Times, Get Certified By India's Top Business News Brand
Stock Trading
Renko Chart Patterns Made Easy
By — Kaushik Akiwatkar, Derivative Trader and Investor
Stock Trading
Candlesticks Made Easy: Candlestick Pattern Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Dow Theory Made Easy
By — Vishal Mehta, Independent Systematic Trader
Stock Trading
Market 101: